2026 ICD-10-CM Diagnosis Code D68.312Antiphospholipid antibody with hemorrhagic disorder
ICD-10-CM Codes›D50–D89›D65-D69›D68
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Chronic Condition
D68.312 is a billable ICD-10-CM diagnosis code for antiphospholipid antibody with hemorrhagic disorder. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 814 through 816. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 52 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Coagulation and hemorrhagic disorders.
D68.312 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 48 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 48, ESRD (V21) category 48, and ESRD (V24) category 48 for payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
D68.312 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Lupus anticoagulant (LAC) with hemorrhagic disorder
- Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder
Type 1 Excludes
- antiphospholipid antibody, finding without diagnosis R76.0
- lupus anticoagulant LAC finding without diagnosis R76.0
- systemic lupus erythematosus [SLE] inhibitor finding without diagnosis R76.0
Type 2 Excludes
- antiphospholipid antibody syndrome D68.61
- antiphospholipid antibody with hypercoagulable state D68.61
- lupus anticoagulant LAC with hypercoagulable state D68.62
- systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state D68.62
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
hemorrhagic disorder D68.312
antiphosphatidylglycerol R76.0
hemorrhagic disorder D68.312
antiphosphatidylinositol R76.0
hemorrhagic disorder D68.312
hemorrhagic disorder D68.312
hemorrhagic disorder D68.312
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Patient EducationClinical
Autoimmune Diseases
Your immune system protects you from disease and infection by attacking germs that get into your body, such as viruses and bacteria. Your immune system can tell that the germs aren't part of you, so it destroys them. If you have an autoimmune disease, your immune system attacks the healthy cells of your organs and tissues by mistake.
The full article covers:
- What are autoimmune diseases?
- What causes autoimmune diseases?
- Who is at risk for autoimmune diseases?
- What are the symptoms of autoimmune diseases?
- How are autoimmune diseases diagnosed?
- What are the treatments for autoimmune diseases?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D68.312 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D68.312Overview
What is the ICD-10 code for antiphospholipid antibody with hemorrhagic disorder?
The ICD-10-CM code for antiphospholipid antibody with hemorrhagic disorder is D68.312 (sometimes written as D68312). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is D68.312 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report antiphospholipid antibody with hemorrhagic disorder on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does D68.312 group to?
When antiphospholipid antibody with hemorrhagic disorder is the principal diagnosis on an inpatient stay, it groups to MS-DRG 814, 815, 816, with relative weights from 0.6320 to 2.1267 depending on complications. Higher weights mean higher Medicare reimbursement.
Is D68.312 a CC or MCC?
CMS lists D68.312 as a CC (complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 52 closely related codes in its exclusion list.
What is the ICD-9 equivalent of D68.312?
Under the General Equivalence Mappings, antiphospholipid antibody with hemorrhagic disorder converts to ICD-9-CM 286.53 (antiphospholipid w hemor). The mapping is a direct match.
Does D68.312 risk-adjust for Medicare Advantage payment?
Not for Medicare Advantage. D68.312 mapped to HCC 48 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 48 (Coagulation Defects and Other Specified Hematological Disorders), ESRD (V21) category 48 (Coagulation Defects and Other Specified Hematological Disorders), and ESRD (V24) category 48 (Coagulation Defects and Other Specified Hematological Disorders).
